Harbour BioMed Seals $175 Million Collaboration with AstraZeneca

In a landmark agreement, Harbour BioMed has entered into a strategic partnership with AstraZeneca, facilitated by Goodwin's Life Sciences team. The collaboration focuses on the discovery and development of next-generation multi-specific antibodies for use in immunology, oncology, and other therapeutic areas. AstraZeneca will be able to license multiple programs from Harbour BioMed, leveraging its Harbour Mice fully human antibody technology platform. Harbour BioMed is set to receive $175 million upfront, plus potential milestones and royalties totaling up to $4.4 billion. The collaboration allows for the inclusion of additional programs over the next five years, potentially extending the agreement for another five years. The collaboration marks a significant advancement for Harbour BioMed in expanding its global biopharmaceutical footprint.